1. ALLA AKTIER
  2. NYHETER
  3. PROSTALUND

ProstaLund

Nyheter ProstaLund Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

First CoreTherm® Eagle treatments performed in Denmark

The first patients in Denmark with benign prostatic hyperplasia have now been successfully treated using ProstaLund’s new CoreTherm® Eagle. The treatments were carried out at Gentofte Hospital, marking the first clinic outside Sweden to adopt the new platform – a significant milestone in the international rollout.

“We are excited to see our first clinic outside Sweden now up and running with CoreTherm® Eagle. The successful treatments of the first patients in Denmark mark yet another important milestone in our continued rollout. Next step is to expand beyond the Nordic region, bringing the benefits of CoreTherm® Eagle to a broader international market,” says Malin Melander, acting CEO and COO at ProstaLund.

“We have now started treatment with the new CoreTherm® Eagle and everything has gone beyond expectations,” says Dr. Lilli Winck-Flyvholm, Senior Consultant in Urology at Gentofte Hospital.

CoreTherm® Eagle builds on more than 25 years of clinical experience from earlier CoreTherm® platforms, used in over 30,000 treatments for benign prostatic hyperplasia. The new platform includes major technical advancements, such as automated calculation of treatment goals and an improved user interface, providing increased support and ease of use for healthcare professionals.

For further information, please contact:

Malin Melander, acting CEO and Chief Operating Officer
Telefon: + 46 (0) 735 24 79 51
E-post: malin.melander@prostalund.com

About CoreTherm®

CoreTherm® is a minimally invasive transurethral microwave thermotherapy for benign prostatic enlargement (BPH). The treatment is performed in an outpatient setting under local anaesthesia and takes less than 15 minutes. No general anaesthesia or spinal block is needed. Follow-up data five years after CoreTherm® treatment shows clinical outcomes comparable to those seen after surgery/TURP (transurethral resection of the prostate), but with lower risk of serious complications. For more information visit, www.coretherm.com.

About ProstaLund

ProstaLund AB (publ) is a Swedish medtech company headquartered in Lund that develops and markets innovative products for the treatment of Benign Prostatic Enlargement (BPH). The company has patented the CoreTherm® Concept, a customised thermal treatment for BPE. ProstaLund is listed on Nasdaq First North Growth Market and has approximately 3,500 shareholders. For more information, visit www.prostalund.se. Our press releases are also available to read and download here: www.prostalund.se/pressmeddelanden

Certified Adviser:
Västra Hamnen Corporate Finance AB
Phone: +46 40 200 250
E-mail: ca@vhcorp.se

Attachments

First CoreTherm® Eagle treatments performed in Denmark

Datum 2025-06-26, kl 16:45
Källa MFN
Bifogade filer
First CoreTherm® Eagle treatments performed in Denmark